• Congxiao Zhang, Haini Li, Jing Gao, Xiaoqing Cui, Shengmei Yang, and Zongtao Liu.
• Qingdao University School of Pharmacy, Department of Pharmacology.
• Medicine (Baltimore). 2021 Jan 29; 100 (4): e24525e24525.

BackgroundAnoctamin-1 (ANO1) plays a pivotal role in cancer progression. A meta-analysis was conducted to assess the potential prognostic role of ANO1 in cancers.MethodsA total of 1760 patients from 7 eligible studies were included into the analysis. Pooled hazard ratios or odds ratios were extracted and calculated with a random-effects model, and analyses of heterogeneity bias were conducted.ResultsOur results showed that over expression of ANO1 was significantly correlated with poor overall survival in all cancers (HR = 1.52; 95% CI: 1.19-1.92; P = .0006). Subgroup analysis indicated that there was a significant association between over expression of ANO1 and poor prognosis breast cancer (HR = 3.24; 95% CI: 1.74-6.04), head and neck squamous cell carcinoma (HR = 1.14; 95% CI: 1.00-1.30), esophageal squamous cell carcinoma (HR = 1.93; 95% CI: 1.07-3.50), gastric cancer (HR = 1.62; 95% CI: 1.12-2.34) and colorectal cancer (HR = 1.38; 95% CI: 1.03-1.85). In addition, over expression of ANO1 was not associated with TNM stage, histological grade, lymph node metastasis, tumor size, age and gender. However, ANO1 was significantly associated with human epidermal growth factor receptor 2, but not associated with progesterone receptor or estrogen receptor in breast cancer.ConclusionsOur results indicate that ANO1 can be a predictive factor for prognosis of cancer.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

14 keywords...

hide…